DOI QR코드

DOI QR Code

Gemcitabine-based Concurrent Chemoradiotherapy Versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer

  • Wang, Bu-Hai (Department of Oncology of Subei People's Hospital, Yangzhou University) ;
  • Cao, Wen-Miao (Department of Oncology of Subei People's Hospital, Yangzhou University) ;
  • Yu, Jie (Department of Oncology of Subei People's Hospital, Yangzhou University) ;
  • Wang, Xiao-Lei (Department of Oncology of Subei People's Hospital, Yangzhou University)
  • Published : 2012.05.30

Abstract

Objective: To explore improved treatment by retrospectively comparing survival time of gemcitabine-based concurrent chemoradiotherapy (GemRT) versus chemotherapy (Gem) alone in patients with locally advanced pancreatic cancer (LAPC). Methods: From January 2005 to June 2010, 56 patients with LAPC from Subei People's Hospital were treated either with Gem (n=21) or GemRT (n=35). Gem consisted of 4-6 cycles gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle). GemRT consisted of 50.4Gy/28F radiotherapy with concurrent 2 cycles of gemcitabine (1000 $mg/m^2$ on days of radiation 1, 8, 15, 21-day a cycle). Radiation was delivered to the gross tumor volume plus 1-1.5 cm by use of a three-dimensional conformal technique. The follow-up time was calculated from the time of diagnosis to the date of death or last contact. Kaplan-Meier methodology wes used to evaluate survival. Results: Patient characteristics were not significantly different between treatment groups. The disease control rate and the objective response rate of GemRT versus Gem was 97.1% vs 71.4%, 74.3% vs 38.1%. The overall survival (OS) was significantly better for GemRT compared to Gem (median 13 months versus 8 months; 51.4% versus 14.3% at 1 year, respectively). Conclusion: Radiation therapy at 50.4Gy with 2 concurrent cycles of gemcitabine results in favorable rates of OS. Concurrent chemoradiotherapy should be the first choice for patients with LAPC.

Keywords

References

  1. Banu E, Banu A, Fodor A, et al (2007). Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging, 24, 865. https://doi.org/10.2165/00002512-200724100-00006
  2. Bria E, Milella M, Gelibter A, et al (2007). Gemcitabine based combinations for inoperable pancreatic cancer: Have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer, 110, 525. https://doi.org/10.1002/cncr.22809
  3. Brunner TB, Scott-Brown M (2010). The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol, 5, 64. https://doi.org/10.1186/1748-717X-5-64
  4. Burris HA, Moore MJ, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15, 2403-13. https://doi.org/10.1200/JCO.1997.15.6.2403
  5. Hidalgo M (2010). Pancreatic cancer. N Engl J Med, 362, 1605-17. https://doi.org/10.1056/NEJMra0901557
  6. Hunter KU, Feng FY, Griffith KA, et al (2011). Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys, 83, 921-6.
  7. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66. https://doi.org/10.3322/canjclin.57.1.43
  8. Li D, Xie K, Wolff R, et al (2010). Pancreatic cancer. Lancet, 1363, 1049-57.
  9. Loehrer PJ Sr, Feng Y, Cardenes H, et al (2011). Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol, 29, 4105-12. https://doi.org/10.1200/JCO.2011.34.8904
  10. Ni QX, Fu DL (2006). Combined therapy based on tumor biology characteristic for advanced pancretic cancer. Theory Pract Surg, 11, 471-7.
  11. Sener SF, Fremgen A (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg, 189, 1-7. https://doi.org/10.1016/S1072-7515(99)00075-7
  12. Sultana A, Smith CT, Cunningham D, et al (2007). Met-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 25, 2607. https://doi.org/10.1200/JCO.2006.09.2551
  13. Zhu CP, Shi J, Chen YX, et al (2011). Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis. Radiother Oncol, 99, 108-13. https://doi.org/10.1016/j.radonc.2011.04.001

Cited by

  1. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway vol.12, pp.5, 2015, https://doi.org/10.3892/mmr.2015.4379
  2. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer vol.39, pp.1, 2016, https://doi.org/10.1097/COC.0000000000000022
  3. Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and meta-analysis pp.17437555, 2018, https://doi.org/10.1111/ajco.12996